Cargando…
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
Current anti-retroviral treatment (ART) for HIV is effective in maintaining HIV at undetectable levels. However, cessation of ART results in immediate and brisk rebound of viremia to high levels. This rebound is driven by an HIV reservoir mainly enriched in memory CD4(+) T cells. In order to provide...
Autores principales: | Zaidi, Asifa, Meng, Qinglai, Popkin, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841618/ https://www.ncbi.nlm.nih.gov/pubmed/27110598 http://dx.doi.org/10.4172/imt.1000104 |
Ejemplares similares
-
In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
por: Tomalka, Amanda G., et al.
Publicado: (2018) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017) -
Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016) -
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)